Obstructive sleep apnoea/hypopnoea syndrome linked to NTG

Article

Moderate and severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is strongly linked to normal tension glaucoma (NTG).

Moderate and severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is strongly linked to normal tension glaucoma (NTG), claims a study in the Journal of Glaucoma.

Dr Pei-Wen Lin et al., Department of Ophthalmology, Kaohsiung Medical Center, Taiwan, conducted a polysomnographic exam on 256 participants to diagnose OSAHS. A complete ophthalmologic examination was performed on all participants. This included best-corrected visual acuity (BCVA), intraocular pressure, slit lamp biomicroscopy, gonioscopy, fundoscopy, automated visual field (VF) and retinal nerve fibre layer (RNFL) evaluation.

OSAHS was found in 209 patients out of the total examined and 38 were placed into the normal group. In the OSAHS group NTG was discovered in 12 patients. The prevalence was 5.7% - significantly higher than the normal group. Out of the NTG patients examined, one was found to have mild OSAHS, three were moderate and eight were severe.

Prevalence of NTG in moderate and severe OSAHS patients was 7.1%. This was significantly higher than normal and mild OSAHS patients. There were no incidences of glaucoma in the normal group.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.